Compare Stocks

Date Range: 

 INSYS TherapeuticsBenitec BiopharmaInMed PharmaceuticalsMidatech PharmaAmarillo Biosciences
SymbolNASDAQ:INSYNASDAQ:BNTCNASDAQ:INMNASDAQ:MTPOTCMKTS:AMAR
Price Information
Current PriceN/A$4.35$3.45$2.09$0.65
52 Week RangeN/AHoldBuyN/AN/A
MarketRank™
Overall Score1.00.61.70.70.5
Analysis Score0.00.03.50.00.0
Community Score2.72.35.03.02.6
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.00.0
Earnings & Valuation Score0.60.60.00.60.0
Analyst Ratings
Consensus RecommendationN/AHoldBuyN/AN/A
Consensus Price TargetN/AN/A$11.50N/AN/A
% Upside from Price TargetN/AN/A233.33% upsideN/AN/A
Trade Information
Market Cap$21.71 million$20.96 million$28.34 million$26.49 million$32.18 million
Beta3.211.84N/A2.63-0.3
Average Volume9,520,5922,053,399187,372698,96419,392
Sales & Book Value
Annual Revenue$82.08 million$100,000.00N/A$860,000.00$10,000.00
Price / Sales0.00209.58N/A30.812,734.29
CashflowN/A$4.39 per shareN/AN/AN/A
Price / CashN/A0.99N/AN/AN/A
Book Value($0.58) per share$19.75 per shareN/A$40.82 per shareN/A
Price / Book0.000.22N/A0.05∞
Profitability
Net Income$-124,510,000.00$-8,270,000.00N/A$-12,880,000.00$-1,580,000.00
EPS($1.39)($8.10)N/AN/AN/A
Trailing P/E RatioN/AN/A0.000.000.00
Forward P/E RatioN/A∞N/A∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-346.61%N/AN/AN/A-7,434.30%
Return on Equity (ROE)-1,430.37%N/AN/AN/AN/A
Return on Assets (ROA)-64.04%N/AN/AN/A-320.19%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.02%N/A
Current Ratio0.54%N/AN/A1.40%0.15%
Quick Ratio0.50%N/AN/AN/A0.14%
Ownership Information
Institutional Ownership Percentage14.93%5.72%N/A2.27%N/A
Insider Ownership Percentage65.40%1.00%N/AN/AN/A
Miscellaneous
Employees22614N/A652
Shares Outstanding74.57 million4.82 million8.05 million12.68 million42.07 million
Next Earnings DateN/AN/A5/13/2021 (Confirmed)6/21/2021 (Estimated)5/21/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
bignewsnetwork.com - April 21 at 6:27 PM
Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
bignewsnetwork.com - April 21 at 6:27 PM
Three Hicks Thomas Attorneys Named to 2021 List of Texas Rising StarsThree Hicks Thomas Attorneys Named to 2021 List of Texas Rising Stars
apnews.com - March 25 at 8:45 PM
NY state Assembly hires top law firm for Cuomo investigationNY state Assembly hires top law firm for Cuomo investigation
newschannel10.com - March 17 at 2:15 PM
Global Thrombocytopenia Management Market 2020 Industry Growth Analysis by Key Players, Segments, Competitive Landscape and Forecast to 2025Global Thrombocytopenia Management Market 2020 Industry Growth Analysis by Key Players, Segments, Competitive Landscape and Forecast to 2025
marketwatch.com - February 8 at 8:37 AM
Amarillo Biosciences, Inc.: Amarillo Biosciences, Ind. Enters into a Securities Purchase Agreement to Foster New GrowthAmarillo Biosciences, Inc.: Amarillo Biosciences, Ind. Enters into a Securities Purchase Agreement to Foster New Growth
finanznachrichten.de - January 1 at 4:02 AM
Amarillo Biosciences, Ind. Enters into a Securities Purchase Agreement to Foster New GrowthAmarillo Biosciences, Ind. Enters into a Securities Purchase Agreement to Foster New Growth
benzinga.com - December 30 at 4:13 PM
Thrombocytopenia Treatment Market Growth 2026 Trend & Forecast ReportThrombocytopenia Treatment Market Growth 2026 Trend & Forecast Report
marketwatch.com - December 24 at 9:41 AM
News for Amarillo Biosciences IncNews for Amarillo Biosciences Inc
markets.businessinsider.com - December 24 at 4:40 AM
Thrombocytopenia Management Market to Witness heightened Growth with Extension of COVID-19 PandemicThrombocytopenia Management Market to Witness heightened Growth with Extension of COVID-19 Pandemic
pharmiweb.com - December 19 at 10:20 PM
Akers runs wild, Newton benched as Rams rout Patriots 24-3Akers runs wild, Newton benched as Rams rout Patriots 24-3
myhighplains.com - December 11 at 3:27 AM
Fred Akers, Texas coach who flirted with glory, dies at 82Fred Akers, Texas coach who flirted with glory, dies at 82
myhighplains.com - December 7 at 9:56 PM
Medicine expert joins faculty of Texas Tech School of Veterinary MedicineMedicine expert joins faculty of Texas Tech School of Veterinary Medicine
everythinglubbock.com - December 5 at 10:17 PM
Sundman Joins Growing Team Of School Faculty In TexasSundman Joins Growing Team Of School Faculty In Texas
bovinevetonline.com - December 3 at 4:52 PM
New York animal health expert joins vet school facultyNew York animal health expert joins vet school faculty
dailytoreador.com - December 3 at 4:52 PM
No, your ice cream supply won’t be jeopardized by ultra-cold COVID-19 vaccinesNo, your ice cream supply won’t be jeopardized by ultra-cold COVID-19 vaccines
kxan.com - November 11 at 10:29 PM
U.K. Boosts Testing as Johnson Seeks Lockdown Exit StrategyU.K. Boosts Testing as Johnson Seeks Lockdown Exit Strategy
uk.finance.yahoo.com - November 4 at 1:48 PM
Amarillo Biosciences IncAmarillo Biosciences Inc
bloomberg.com - October 22 at 10:16 PM
Influenzavirus B Infection Drug Market Business Growth, Industry Research, Top Key Players Survey- Market.BizInfluenzavirus B Infection Drug Market Business Growth, Industry Research, Top Key Players Survey- Market.Biz
eturbonews.com - October 21 at 8:34 PM
Amarillo Biosciences Inc. (AMAR)Amarillo Biosciences Inc. (AMAR)
nasdaq.com - October 20 at 12:48 AM
New COVID-19 Projections Show Resurgence Risk Moving North to South, Some Stabilization in NortheastNew COVID-19 Projections Show Resurgence Risk Moving North to South, Some Stabilization in Northeast
wfmz.com - October 16 at 11:56 PM
Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory BoardAmarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board
finance.yahoo.com - September 10 at 2:12 PM
Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support RelatedAmarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related
bloomberg.com - August 29 at 8:43 PM
Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related TherapeuticsAmarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics
finance.yahoo.com - August 13 at 6:21 PM
New Research: Home and Work Demands Require Women Rapidly Recover After Surgery but Medication Choices Delay their ReboundNew Research: Home and Work Demands Require Women Rapidly Recover After Surgery but Medication Choices Delay their Rebound
www.prnewswire.com - July 15 at 12:50 PM
DateCompanyBrokerageAction
5/14/2019INSYS TherapeuticsJanney Montgomery ScottDowngrade
3/8/2019INSYS TherapeuticsPiper Jaffray CompaniesSet Price Target
3/8/2019INSYS TherapeuticsRoyal Bank of CanadaLower Price Target
1/22/2019INSYS TherapeuticsCantor FitzgeraldInitiated Coverage
8/10/2018INSYS TherapeuticsJefferies Financial GroupReiterated Rating
10/5/2020Benitec BiopharmaLADENBURG THALM/SH SHDowngrade
2/16/2021InMed PharmaceuticalsRoth CapitalLower Price Target
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.